ARCUTIS BIOTHERAPEUTICS ($ARQT) posted quarterly earnings results on Tuesday, May 6th. The company reported earnings of -$0.20 per share, beating estimates of -$0.21 by $0.01. The company also reported revenue of $65,849,999, beating estimates of $63,495,000 by $2,354,999.
You can see Quiver Quantitative's $ARQT stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ARCUTIS BIOTHERAPEUTICS Insider Trading Activity
ARCUTIS BIOTHERAPEUTICS insiders have traded $ARQT stock on the open market 36 times in the past 6 months. Of those trades, 3 have been purchases and 33 have been sales.
Here’s a breakdown of recent trading of $ARQT stock by insiders over the last 6 months:
- PATRICK BURNETT (See Remarks) has made 0 purchases and 12 sales selling 166,829 shares for an estimated $2,062,043.
- TODD FRANKLIN WATANABE (See Remarks) has made 1 purchase buying 2,038 shares for an estimated $14,482 and 8 sales selling 75,635 shares for an estimated $1,059,175.
- HOWARD G. WELGUS has made 0 purchases and 6 sales selling 60,000 shares for an estimated $826,588.
- MASARU MATSUDA (See Remarks) has made 1 purchase buying 1,657 shares for an estimated $11,774 and 4 sales selling 18,406 shares for an estimated $242,056.
- DAVID JOSEPH TOPPER (Chief Financial Officer) sold 9,600 shares for an estimated $151,698
- TERRIE CURRAN sold 8,687 shares for an estimated $94,238
- LARRY TODD EDWARDS (See Remarks) has made 1 purchase buying 1,093 shares for an estimated $7,766 and 1 sale selling 2,173 shares for an estimated $27,597.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ARCUTIS BIOTHERAPEUTICS Hedge Fund Activity
We have seen 105 institutional investors add shares of ARCUTIS BIOTHERAPEUTICS stock to their portfolio, and 104 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC removed 2,941,905 shares (-97.1%) from their portfolio in Q4 2024, for an estimated $40,980,736
- UBS GROUP AG added 2,569,336 shares (+1166.9%) to their portfolio in Q4 2024, for an estimated $35,790,850
- POINT72 ASSET MANAGEMENT, L.P. added 1,509,136 shares (+617.5%) to their portfolio in Q4 2024, for an estimated $21,022,264
- PERCEPTIVE ADVISORS LLC removed 1,358,500 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $18,923,905
- STEMPOINT CAPITAL LP removed 1,277,352 shares (-71.8%) from their portfolio in Q4 2024, for an estimated $17,793,513
- CERCANO MANAGEMENT LLC added 1,255,365 shares (+inf%) to their portfolio in Q4 2024, for an estimated $17,487,234
- MILLENNIUM MANAGEMENT LLC added 1,162,690 shares (+101.3%) to their portfolio in Q4 2024, for an estimated $16,196,271
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ARCUTIS BIOTHERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $ARQT in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Buy" rating on 03/11/2025
- H.C. Wainwright issued a "Buy" rating on 12/30/2024
To track analyst ratings and price targets for ARCUTIS BIOTHERAPEUTICS, check out Quiver Quantitative's $ARQT forecast page.
ARCUTIS BIOTHERAPEUTICS Price Targets
Multiple analysts have issued price targets for $ARQT recently. We have seen 2 analysts offer price targets for $ARQT in the last 6 months, with a median target of $19.0.
Here are some recent targets:
- An analyst from Jefferies set a target price of $19.0 on 03/11/2025
- Douglas Tsao from H.C. Wainwright set a target price of $19.0 on 12/30/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
